Vogt-Koyanagi-Harada disease

International Ophthalmology Clinics

Volumn 46, Issue 2, 2006, Pages 111-122

  Andreoli, Christopher M ^a   Stephen Foster, C ^b  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b Massachusetts Eye Research and Surgery Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; CYTOSTATIC AGENT; CYTOTOXIC AGENT; DACLIZUMAB; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS;

ALOPECIA; ARTERIOVENOUS FISTULA; AUTOIMMUNE DISEASE; BIOMICROSCOPY; BONE MARROW SUPPRESSION; CATARACT; CATARACT EXTRACTION; CELLULAR IMMUNITY; CHOROID HEMORRHAGE; CHRONIC INFLAMMATION; CLOSED ANGLE GLAUCOMA; CONFERENCE PAPER; CORTICOSTEROID THERAPY; DEPIGMENTATION; DIABETES MELLITUS; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DRUG INDUCED CANCER; DRUG MEGADOSE; ECHOGRAPHY; EYE SYNECHIA; FLUORESCENCE ANGIOGRAPHY; GASTROINTESTINAL SYMPTOM; GENETIC LINKAGE; GUM HYPERPLASIA; HEMATURIA; HEMORRHAGIC CYSTITIS; HEPATITIS; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERPLASIA; HYPERTENSION; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; IMPOTENCE; INFECTION; INFERTILITY; IRIDOCYCLITIS; IRIS ATROPHY; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER TOXICITY; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; OCULAR FIBROSIS; PATHOGENESIS; PLEOCYTOSIS; PRIORITY JOURNAL; PUNCTURE; RETINA PIGMENT DEGENERATION; SUBRETINAL NEOVASCULARIZATION; SYSTEMIC DISEASE; TOXIC HEPATITIS; TRABECULECTOMY; TREMOR; UREMIA; UVEITIS; VISUAL ACUITY; VOGT KOYANAGI SYNDROME; VOMITING;

EID: 33746112541     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004397-200604620-00011     Document Type: Conference Paper

References (61)

1. Koyanagi Y. Dysakusis, Alopecia und Poliosis bei schwerer Uveitis nicht traumatischen Ursprugs. Klin Monatsbl Augenheilkd. 1929;82:194-211.
2. Vogt A. Fruhzeitiges Ergaruen der Zilien und Bemerkungen uber den sogenaten plotzlichen Eintreitt dieser Veranderung. Klin Monatsbl Augenheilkd. 1906;44:228-242.
3. Harada E. Acute diffuse choroiditis. Acta Soc Ophthalmol Jpn. 1926;30:356-378.
4. Babel J. Sundrome de Vogt-Koyanagi (Uveite bilaterale, poliosis, alopecie, vitiligo et dyacousie). Schweiz Med Wochenschr Nr. 1932;44:1136-1140.
5. Ohno S, Minakawa R, Matsuda H. Clinical studies of Vogt-Koyanagi-Harada's disease. Jpn J Ophthalmol. 1988;32:334-343.
6. Rao NA. Mechanisms of inflammatory response in sympathetic ophthalmia and VKH syndrome. Eye. 1997;11:213-216.
7. Inomata H, Rao NA. Depigmented atrophic lesions in sunset glow fundi of Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2001;131:607-614.
8. Friedman AH, Deutsch-Sokol RH. Sugiura's sign. Perilimbal vitiligo in the Vogt-Koyanagi-Harada syndrome. Ophthalmology. 1981;88:1159-1165.
9. Taylor S, Lightman S. Recurrent anterior uveitis in patients with Vogt-Koyanagi-Harada syndrome. Arch Ophthalmol. 2004;122:922-923.
10. Read RW, Rechodouni A, Butani N, et al. Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2001;131:599-606.
11. Kuo IC, Rechdouni A, Rao NA, et al. Subretinal fibrosis in patients with Vogt-Koyanagi-Harada disease. Ophthalmology. 2000;107:1721-1728.
12. Rubsamen PE, Gass JD. Vogt-Koyanagi-Harada syndrome. Clinical course, therapy, and long-term visual outcome. Arch Ophthalmol. 1991;109:682-687.
13. Pezzi PP, Paroli MP, Priori R, et al. Vogt-Koyanagi-Harada syndrome and kerato-conjunctivitis sicca. Am J Ophthalmol. 2004;137:769-770.
14. Najman-Vainer J, Levinson RD, Graves MC, et al. An association between Vogt-Koyanagi-Harada disease and Guillain-Barre syndrome. Am J Ophthalmol. 2001; 131:615-619.
15. Yawata N, Nakamura S, Kijima M, et al. High incidence of glucose intolerance in Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 1999;83:39-42.
16. Shindo Y, Inoko H, Yamamoto T, et al. HLA-DRB1 typing of Vogt-Koyanagi-Harada's disease by PCR-RFLP and the strong association with DRB1*0405 and DRB1*0410. Br J Ophthalmol. 1994;78:223-226.
17. Islam SM, Numaga J, Fujino Y, et al. HLA class II genes in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 1994;35:3890-3896.
18. Shindo Y, Ohno S, Yamamoto T, et al. Complete association of the HLA-DRB1*04 and -DQB1*04 alleles with Vogt-Koyanagi-Harada's disease. Hum Immunol. 1994; 39:169-176.
19. Weisz JM, Holland GN, Roer LN, et al. Association between Vogt-Koyanagi-Harada syndrome and HLA-DR1 and -DR4 in Hispanic patients living in southern California. Ophthalmology. 1995;102:1012-1015.
20. Kim MH, Seong MC, Kwak NH, et al. Association of HLA with Vogt-Koyanagi-Harada syndrome in Koreans. Am J Ophthalmol. 2000;129:173-177.
21. Pivetti-Pezzi P, Accorinti M, Colabelli-Gisoldi RA, et al. Vogt-Koyanagi-Harada disease and HLA type in Italian patients. Am J Ophthalmol. 1996;122:889-891.
22. Arellanes-Garcia L, Bautista N, Mora P, et al. HLA-DR is strongly associated with Vogt-Koyanagi-Harada disease in Mexican Mestizo patients. Ocul Immunol Inflamm. 1998;6:93-100.
23. Zhao M, Jiang Y, Abrahams IW. Association of HLA antigens with Vogt-Koyanagi-Harada syndrome in a Han Chinese population. Arch Ophthalmol. 1991;109:368-370.
24. Itho S, Kurimoto S, Kouno T. Vogt-Koyanagi-Harada disease in monozygotic twins. Int Ophthalmol. 1992;16:49-54.
25. Sakamoto T, Murata T, Inomata H. Class II major histocompatibility complex on melanocytes of Vogt-Koyanagi-Harada disease. Arch Ophthalmol. 1991;109:1270-1274.
26. Norose K, Yano A, Aosai F, et al. Immunologic analysis of cerebrospinal fluid lymphocytes in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 1990; 31:1210-1216.
27. Gocho K, Kondo I, Yamaki K. Identification of autoreactive T cells in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 2001;42:2004-2009.
28. Yamaki K, Gocho K, Sakuragi S. Pathogenesis of Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin. 2002;42:13-23.
29. Perry HD, Font RL. Clinical and histopathologic observations in severe Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 1977;83:242-254.
30. Lubin JR, Ni C, Albert DM. Clinicopathological study of the Vogt-Koyanagi-Harada syndrome. Int Ophthalmol Clin. 1982;22:141-156.
31. Bassili SS, Peyman GA, Gebhardt BM, et al. Detection of Epstein-Barr virus DNA by polymerase chain reaction in the vitreous from a patient with Vogt-Koyanagi-Harada syndrome. Retina. 1996;16:160-161.
32. Rathinam SR, Namperumalsamy P, Nozik RA, et al. Vogt-Koyanagi-Harada syndrome after cutaneous injury. Ophthalmology. 1999;106:635-638.
33. Harada T, Kanbara Y, Takeuchi T, et al. Exploration of Vogt-Koyanagi-Harada syndrome by infrared choroidal angiography with indocyanine green. Eur J Ophthalmol. 1997;7:163-170.
34. Bouchenaki N, Herbort CP. The contribution of indocyanine green angiography to the appraisal and management of Vogt-Koyanagi-Harada disease. Ophthalmology. 2001;108:54-64.
35. Ohno S, Char DH, Kimura SJ, et al. Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 1977;83:735-740.
36. Forster DJ, Cano MR, Green RL, et al. Echographic features of the Vogt-Koyanagi-Harada syndrome. Arch Ophthalmol. 1990;108:1421-1426.
37. Wada S, Kohno T, Yanagihara N, et al. Ultrasound biomicroscopic study of ciliary body changes in the post-treatment phase of Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 2002;86:1374-1379.
38. Snyder DA, Tessler HH. Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 1980;90:69-75.
39. Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131:647-652.
40. Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol. 1995;39:265-292.
41. Goto H, Rao NA. Sympathetic ophthalmia and Vogt-Koyanagi-Harada syndrome. Int Ophthalmol Clin. 1990;30:279-285.
42. Fujioka T, Fukuda M, Okinami S. [A statistic study of Vogt-Koyanagi-Harada syndrome (author's transl)]. Nippon Ganka Gakkai Zasshi. 1980;84:1979-1982.
43. Sasamoto Y, Ohno S, Matsuda H. Studies on corticosteroid therapy in Vogt-Koyanagi-Harada disease. Ophthalmologica. 1990;201:162-167.
44. Yamanaka E, Ohguro N, Yamamoto S, et al. Evaluation of pulse corticosteroid therapy for Vogt-Koyanagi-Harada disease assessed by optical coherence tomography. Am J Ophthalmol. 2002;134:454-456.
45. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492-513.
46. Rao NA. Management of intraocular inflammation. In: Ryan SJ, ed. Retina. 2 vol. 3rd ed. Philadelphia: Mosby; 2001.
47. Paredes I, Ahmed M, Foster CS. Immunomodulatory therapy for VKH patients as first line therapy. Ocul Immunol Inflamm. 2006;14:87-90.
48. Ryan SJ. Retina. 2 vol. 3rd ed. Philadelphia: Mosby; 2001.
49. Rao NA, Blackman HJ, Franklin RM, et al. Intraocular inflammation and uveitis. Basic and Clinical Science Course 1998-1999. San Francisco: American Academy of Ophthalmology; 1998:76-79.
50. Foster CS, Vitale AT. Immunosuppressive Chemotherapy. In: Foster C, Vitale A, eds. Diagnosis and Treatment of Uveitis. New York: W.B. Saunders Company; 2002:177-214.
51. Nussenblatt RB, Palestine AG, Chan CC. Cyclosporine therapy for uveitis: long-term followup. J Ocul Pharmacol. 1985;1:369-382.
52. Wakefield D, McCluskey P, Reece G. Cyclosporin therapy in Vogt Koyanagi Harada disease. Aust N Z J Ophthalmol. 1990;18:137-142.
53. Vitale AT, Rodriguez A, Foster CS. Low-dose cyclosporin A therapy in treating chronic, noninfectious uveitis. Ophthalmology. 1996;103:365-373; discussion 373-374.
54. Wakatsuki Y, Kogure M, Takahashi Y, et al. Combination therapy with cyclosporin A and steroid in severe case of Vogt-Koyanagi-Harada's disease. Jpn J Ophthalmol. 1988;32:358-360.
55. Hemady R, Tauber J, Foster CS. Immunosuppressive drugs in immune and inflammatory ocular disease. Surv Ophthalmol. 1991;35:369-385.
56. Lustig MJ, Cunningham ET Jr. Use of immunosuppressive agents in uveitis. Curr Opin Ophthalmol. 2003;14:399-412.
57. Goldstein DA, Fontanilla FA, Kaul S, et al. Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology. 2002;109:370-377.
58. Nussenblatt RB, Fortin E, Schiffman R, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci USA. 1999;96:7462-7466.
59. Baltatzis S, Tufail F, Yu EN, et al. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology. 2003;110:1061-1065.
60. Helveston WR, Gilmore R. Treatment of Vogt-Koyanagi-Harada syndrome with intravenous immunoglobulin. Neurology. 1996;46:584-585.
61. Ganesh SK, Padmaja BK, Biswas J. Cataract surgery in patients with Vogt-Koyanagi-Harada syndrome. J Cataract Refract Surg. 2004;30:95-100.